Top

Published in:

01-01-2017 | Case report

Successful treatment by prednisolone for interstitial pneumonia associated with anagrelide in a patient with essential thrombocythemia

Authors: Satoshi Tamaru, Yasutaka Tono, Takeshi Matsumoto, Hiroyasu Oda, Yuka Sugimoto, Toshiro Mizuno, Naoyuki Katayama, Masakatsu Nishikawa

Published in: International Cancer Conference Journal | Issue 1/2017

Abstract

Anagrelide is a cytoreductive agent for essential thrombocythemia and its common side effects are anemia, headache, palpitation, diarrhea, and fluid retention. However, severe pulmonary adverse effects are rare. A 66-year-old Japanese man with essential thrombocythemia presented with hemoptysis 2 months after starting anagrelide treatment. Interstitial pneumonia was diagnosed based on physical and radiographic findings. Discontinuation of anagrelide and institution of corticosteroids resulted in the improvement of interstitial pneumonia. Severe lung injury associated with anagrelide is a rare but an important adverse event that must be addressed when treating interstitial pneumonia.

Kanakura Y, Miyakawa Y, Wilde P et al (2014) Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia. Int J Hematol 100:353–360CrossRefPubMed

Harrison CN, Campbell PJ, Buck G et al (2005) Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 353:33–45CrossRefPubMed

Gisslinger H, Gotic M, Holowiecki J et al (2013) Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood 121:1720–1728CrossRefPubMedPubMedCentral

Raghavan M, Mazer MA, Brink DJ (2003) Severe hypersensitivity pneumonitis associated with anagrelide. Ann Pharmacother 37:1228–1231CrossRefPubMed

Spencer EM, Lawrence DS (2006) ‘Double hit’ from streptococcal pneumonia and hypersensitivity pneumonitis associated with anagrelide. Clin Lab Haematol 28:63–65CrossRefPubMed

Title: Successful treatment by prednisolone for interstitial pneumonia associated with anagrelide in a patient with essential thrombocythemia
Authors: Satoshi Tamaru
Yasutaka Tono
Takeshi Matsumoto
Hiroyasu Oda
Yuka Sugimoto
Toshiro Mizuno
Naoyuki Katayama
Masakatsu Nishikawa
Publication date: 01-01-2017
Publisher: Springer Japan
Published in: International Cancer Conference Journal / Issue 1/2017
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-016-0265-7

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

A case of metastatic renal cell carcinoma showing complete remission after cytoreductive nephrectomy followed by temsirolimus

Novel combination chemotherapy with radiotherapy for prostate squamous cell carcinoma

Remitting seronegative symmetrical synovitis with pitting edema syndrome complicated with primary lung cancer

Successful conservative management of diffuse cavernous hemangioma of the rectum

Transanal approach for intersphincteric resection of rectal cancer in a patient with a huge prostatic hypertrophy

Exacerbation of gemcitabine-related pneumonia during radiotherapy for extrapulmonary lesion

Keynote webinar | Spotlight on antibody–drug conjugates in cancer